Stephen Willey
Stock Analyst at Stifel
(3.22)
# 1,071
Out of 4,749 analysts
121
Total ratings
42.39%
Success rate
3.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Buy | $34 → $36 | $19.71 | +82.65% | 4 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Downgrades: Hold | $27 → $2.5 | $1.51 | +65.56% | 7 | Jan 10, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $5 → $4 | $0.70 | +471.35% | 2 | Nov 14, 2024 | |
| ABCL AbCellera Biologics | Reiterates: Buy | $14 → $12 | $3.17 | +278.55% | 4 | Nov 5, 2024 | |
| ZYME Zymeworks | Maintains: Buy | $21 → $28 | $14.60 | +91.78% | 6 | Oct 28, 2024 | |
| EXEL Exelixis | Maintains: Hold | $26 → $30 | $33.15 | -9.50% | 16 | Oct 16, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $47 | $12.62 | +272.42% | 1 | Oct 8, 2024 | |
| CUE Cue Biopharma | Maintains: Buy | $8 → $4 | $1.45 | +175.86% | 7 | Aug 20, 2024 | |
| INSM Insmed | Maintains: Buy | $74 → $88 | $76.58 | +14.91% | 4 | Aug 9, 2024 | |
| HLVX HilleVax | Downgrades: Hold | $34 → $3 | $1.97 | +52.28% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $2.87 | +143.90% | 2 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $6 → $1.5 | $0.49 | +206.12% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $7 | $3.00 | +133.33% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7 | $2.85 | +145.61% | 10 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $1.42 | +745.07% | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $68 | $74.16 | -8.31% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $2.33 | +71.67% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $39.98 | +55.08% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.34 | +669.23% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.22 | +179.50% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.22 | +272.67% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $2.09 | +13,679.90% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $0.86 | +2,351.55% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $0.76 | +428.96% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $271.31 | -54.66% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $31.90 | +47.34% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $63.36 | +72.03% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $18.64 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $0.27 | +9,221.40% | 5 | Mar 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.33 | +213.78% | 5 | Feb 7, 2018 |
Nurix Therapeutics
Jan 29, 2025
Maintains: Buy
Price Target: $34 → $36
Current: $19.71
Upside: +82.65%
IGM Biosciences
Jan 10, 2025
Downgrades: Hold
Price Target: $27 → $2.5
Current: $1.51
Upside: +65.56%
X4 Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $0.70
Upside: +471.35%
AbCellera Biologics
Nov 5, 2024
Reiterates: Buy
Price Target: $14 → $12
Current: $3.17
Upside: +278.55%
Zymeworks
Oct 28, 2024
Maintains: Buy
Price Target: $21 → $28
Current: $14.60
Upside: +91.78%
Exelixis
Oct 16, 2024
Maintains: Hold
Price Target: $26 → $30
Current: $33.15
Upside: -9.50%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $12.62
Upside: +272.42%
Cue Biopharma
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $1.45
Upside: +175.86%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $74 → $88
Current: $76.58
Upside: +14.91%
HilleVax
Jul 9, 2024
Downgrades: Hold
Price Target: $34 → $3
Current: $1.97
Upside: +52.28%
Jun 10, 2024
Maintains: Buy
Price Target: $6 → $7
Current: $2.87
Upside: +143.90%
May 15, 2024
Downgrades: Hold
Price Target: $6 → $1.5
Current: $0.49
Upside: +206.12%
May 10, 2024
Downgrades: Hold
Price Target: $29 → $7
Current: $3.00
Upside: +133.33%
Apr 12, 2024
Maintains: Hold
Price Target: $7
Current: $2.85
Upside: +145.61%
Mar 21, 2024
Maintains: Buy
Price Target: $15 → $12
Current: $1.42
Upside: +745.07%
Mar 12, 2024
Reiterates: Hold
Price Target: $68
Current: $74.16
Upside: -8.31%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $2.33
Upside: +71.67%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $39.98
Upside: +55.08%
May 12, 2023
Maintains: Buy
Price Target: $21 → $18
Current: $2.34
Upside: +669.23%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $3.22
Upside: +179.50%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $3.22
Upside: +272.67%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $2.09
Upside: +13,679.90%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $0.86
Upside: +2,351.55%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $0.76
Upside: +428.96%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $271.31
Upside: -54.66%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $31.90
Upside: +47.34%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $63.36
Upside: +72.03%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $18.64
Upside: -
Mar 7, 2018
Maintains: Buy
Price Target: $23 → $25
Current: $0.27
Upside: +9,221.40%
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.33
Upside: +213.78%